$12.74
0.191.51%
At close: -
$12.74
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Denali Therapeutics Analyst Ratings and Price Targets | NASDAQ:DNLI | Benzinga
Denali Therapeutics Inc has a consensus price target of $38.79 based on the ratings of 22 analysts. The high is $87 issued by HC Wainwright & Co. on February 28, 2025. The low is $24 issued by JP Morgan on January 7, 2025. The 3 most-recent analyst ratings were released by B of A Securities, Morgan Stanley, and B. Riley Securities on March 10, 2025, March 7, 2025, and March 5, 2025, respectively. With an average price target of $32 between B of A Securities, Morgan Stanley, and B. Riley Securities, there's an implied 151.18% upside for Denali Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
Morgan Stanley
B. Riley Securities
Oppenheimer
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Denali Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/10/2025 | Buy Now | 119.78% | B of A Securities | Tazeen Ahmad55% | $30 → $28 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | 159.03% | Morgan Stanley | Matthew Harrison62% | $41 → $33 | Assumes | → Overweight | Get Alert |
| 03/05/2025 | Buy Now | 174.73% | B. Riley Securities | Mayank Mamtani70% | $38 → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2025 | Buy Now | 229.67% | Oppenheimer | Jay Olson61% | $50 → $42 | Maintains | Outperform | Get Alert |
| 02/28/2025 | Buy Now | 582.89% | HC Wainwright & Co. | Andrew Fein54% | $80 → $87 | Maintains | Buy | Get Alert |
| 02/11/2025 | Buy Now | 143.33% | Deutsche Bank | David Hoang35% | → $31 | Initiates | → Buy | Get Alert |
| 01/28/2025 | Buy Now | 213.97% | Goldman Sachs | Salveen Richter52% | $45 → $40 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | 88.38% | JP Morgan | Jessica Fye63% | $28 → $24 | Maintains | Overweight | Get Alert |
| 01/07/2025 | Buy Now | 582.89% | HC Wainwright & Co. | Andrew Fein54% | $90 → $87 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | 143.33% | Baird | Joel Beatty64% | → $31 | Initiates | → Outperform | Get Alert |
| 01/03/2025 | Buy Now | — | William Blair | Sarah Schram7% | — | Initiates | → Outperform | Get Alert |
| 12/16/2024 | Buy Now | 190.42% | Stifel | Paul Mattels7% | → $37 | Upgrade | Hold → Buy | Get Alert |
| 11/07/2024 | Buy Now | 606.44% | HC Wainwright & Co. | Andrew Fein54% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 11/01/2024 | Buy Now | 253.22% | Jefferies | Michael Yee56% | $40 → $45 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | 119.78% | JP Morgan | Jessica Fye63% | $29 → $28 | Maintains | Overweight | Get Alert |
| 10/10/2024 | Buy Now | — | Raymond James | Danielle Brill41% | — | Reinstates | → Market Perform | Get Alert |
| 09/09/2024 | Buy Now | 174.73% | Cantor Fitzgerald | Charles Duncan68% | $35 → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 09/04/2024 | Buy Now | 606.44% | HC Wainwright & Co. | Andrew Fein54% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 09/04/2024 | Buy Now | 127.63% | B of A Securities | Tazeen Ahmad55% | $25 → $29 | Maintains | Buy | Get Alert |
| 08/15/2024 | Buy Now | 606.44% | HC Wainwright & Co. | Andrew Fein54% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 08/05/2024 | Buy Now | 606.44% | HC Wainwright & Co. | Andrew Fein54% | $95 → $90 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 151.18% | Citigroup | David Hoang35% | $26 → $32 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 104.08% | Wedbush | Laura Chico44% | $30 → $26 | Maintains | Outperform | Get Alert |
| 07/10/2024 | Buy Now | 127.63% | JP Morgan | Jessica Fye63% | $28 → $29 | Maintains | Overweight | Get Alert |
| 05/08/2024 | Buy Now | 645.68% | HC Wainwright & Co. | Andrew Fein54% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 135.48% | Wedbush | Laura Chico44% | $31 → $30 | Maintains | Outperform | Get Alert |
| 05/08/2024 | Buy Now | 72.68% | Stifel | Paul Mattels7% | $26 → $22 | Maintains | Hold | Get Alert |
| 04/09/2024 | Buy Now | 151.18% | UBS | Esther Rajavelu34% | $70 → $32 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 292.46% | Goldman Sachs | Salveen Richter52% | $73 → $50 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 143.33% | Wedbush | Laura Chico44% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 02/28/2024 | Buy Now | 645.68% | HC Wainwright & Co. | Andrew Fein54% | $105 → $95 | Maintains | Buy | Get Alert |
| 02/22/2024 | Buy Now | 724.18% | HC Wainwright & Co. | Andrew Fein54% | $105 → $105 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2023 | Buy Now | 151.18% | Citigroup | David Hoang35% | → $32 | Initiates | → Buy | Get Alert |
| 11/20/2023 | Buy Now | 119.78% | JP Morgan | Jessica Fye63% | → $28 | Reinstates | → Overweight | Get Alert |
| 11/08/2023 | Buy Now | 143.33% | Wedbush | Laura Chico44% | → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2023 | Buy Now | 174.73% | Cantor Fitzgerald | Charles Duncan68% | $85 → $35 | Assumes | → Overweight | Get Alert |
| 09/06/2023 | Buy Now | 198.27% | B. Riley Securities | Mayank Mamtani70% | → $38 | Initiates | → Buy | Get Alert |
| 08/31/2023 | Buy Now | 724.18% | HC Wainwright & Co. | Andrew Fein54% | → $105 | Reiterates | Buy → Buy | Get Alert |
| 08/31/2023 | Buy Now | 567.19% | Cantor Fitzgerald | Charles Duncan68% | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 567.19% | Cantor Fitzgerald | Charles Duncan68% | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 08/10/2023 | Buy Now | 567.19% | Cantor Fitzgerald | Charles Duncan68% | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 143.33% | Wedbush | Laura Chico44% | $37 → $31 | Maintains | Outperform | Get Alert |
| 08/09/2023 | Buy Now | 724.18% | HC Wainwright & Co. | Andrew Fein54% | → $105 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | Buy Now | 567.19% | Cantor Fitzgerald | Charles Duncan68% | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 06/21/2023 | Buy Now | 724.18% | HC Wainwright & Co. | Andrew Fein54% | → $105 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 433.75% | Oppenheimer | Jay Olson61% | $70 → $68 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 190.42% | Wedbush | Laura Chico44% | $38 → $37 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 724.18% | HC Wainwright & Co. | Andrew Fein54% | → $105 | Reiterates | → Buy | Get Alert |
| 04/12/2023 | Buy Now | 394.51% | Morgan Stanley | Matthew Harrison62% | $61 → $63 | Maintains | Overweight | Get Alert |
| 03/02/2023 | Buy Now | 449.45% | Oppenheimer | Jay Olson61% | $85 → $70 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 378.81% | Morgan Stanley | Matthew Harrison62% | $65 → $61 | Maintains | Overweight | Get Alert |
| 02/28/2023 | Buy Now | 292.46% | Evercore ISI Group | Joshua Schimmer44% | $80 → $50 | Maintains | Outperform | Get Alert |
| 02/28/2023 | Buy Now | 724.18% | HC Wainwright & Co. | Andrew Fein54% | → $105 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 198.27% | Wedbush | Laura Chico44% | $46 → $38 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 724.18% | HC Wainwright & Co. | Andrew Fein54% | → $105 | Reiterates | → Buy | Get Alert |
| 01/30/2023 | Buy Now | 292.46% | SVB Leerink | Marc Goodman73% | → $50 | Initiates | → Outperform | Get Alert |
| 01/25/2023 | Buy Now | 410.2% | Morgan Stanley | Matthew Harrison62% | $60 → $65 | Maintains | Overweight | Get Alert |
| 12/05/2022 | Buy Now | — | Cowen & Co. | Brendan Smith45% | — | Initiates | → Outperform | Get Alert |
| 11/08/2022 | Buy Now | 370.96% | Morgan Stanley | Matthew Harrison62% | $67 → $60 | Maintains | Overweight | Get Alert |
| 11/02/2022 | Buy Now | 213.97% | B of A Securities | Avikal Malik4% | → $40 | Initiates | → Buy | Get Alert |
| 06/23/2022 | Buy Now | 206.12% | Berenberg | Caroline Palomeque60% | → $39 | Initiates | → Buy | Get Alert |
| 05/24/2022 | Buy Now | 543.64% | Goldman Sachs | Salveen Richter52% | $99 → $82 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Denali Therapeutics (DNLI) stock?
The latest price target for Denali Therapeutics (NASDAQ:DNLI) was reported by B of A Securities on March 10, 2025. The analyst firm set a price target for $28.00 expecting DNLI to rise to within 12 months (a possible 119.78% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Denali Therapeutics (DNLI)?
The latest analyst rating for Denali Therapeutics (NASDAQ:DNLI) was provided by B of A Securities, and Denali Therapeutics maintained their buy rating.
When was the last upgrade for Denali Therapeutics (DNLI)?
The last upgrade for Denali Therapeutics Inc happened on December 16, 2024 when Stifel raised their price target to $37. Stifel previously had a hold for Denali Therapeutics Inc.
When was the last downgrade for Denali Therapeutics (DNLI)?
There is no last downgrade for Denali Therapeutics.
When is the next analyst rating going to be posted or updated for Denali Therapeutics (DNLI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Denali Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Denali Therapeutics was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.
Is the Analyst Rating Denali Therapeutics (DNLI) correct?
While ratings are subjective and will change, the latest Denali Therapeutics (DNLI) rating was a maintained with a price target of $30.00 to $28.00. The current price Denali Therapeutics (DNLI) is trading at is $12.74, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
